Clinical Commander

Back to dossier
cardio.acute-hf.lupus-myocarditis.v1PRODUCTION
cardio.acute-hf.lupus-myocarditis.v1

ADHF in SLE myocarditis

cardiologyacuteadult
Hard-required inputs
0 / 12
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

SLE myocarditis presenting as ADHF — phenotype-first triage (immunosuppression-responsive vs concurrent ICI-myocarditis vs Libman-Sacks endocarditis with embolic complication)

Inputs
2
Actions
0
Advance rule
Set
Advance when

SLE myocarditis suspected

Patient inputs (15)

SLE confirmation (ANA ≥1:80, anti-dsDNA + anti-Smith specific) + flare activity (low C3/C4 + rising dsDNA)

Lupus anticoagulant + anti-cardiolipin + anti-β2GP1 — drives Libman-Sacks AC decision and stroke risk

Lupus nephritis screen — proteinuria + active sediment changes management (mycophenolate vs cyclophosphamide)

Lake Louise 2018 — T2 active edema + LGE patchy mid-wall non-ischemic distribution

SLE peak incidence 15-45; pediatric SLE more aggressive; late-onset SLE (>50) often milder

F:M ~9:1 reproductive age; cardiac SLE may behave differently across sex

Prior ACR/EULAR-criteria SLE diagnosis or features (malar rash, arthritis, serositis, nephritis, cytopenias, neuropsychiatric)

Lupus nephritis common; baseline before ACEi/ARB/NSAID + cyclophosphamide; KDIGO 2026 staging

HF severity stratification + monitoring response to immunosuppression

Reflects ongoing myocyte injury; trend daily during immunosuppression

LV dysfunction, regional wall motion, pericardial effusion, Libman-Sacks valve thickening / vegetation

Hypotension may indicate myocarditis severity, pericardial tamponade, or vasodilatory state

MANDATORY before high-dose steroids in patients with possible exposure (steroids precipitate fatal hyperinfection)

Endomyocardial biopsy gold standard if life-threatening (CS, fulminant) or atypical presentation per AHA 2020 (PMID 32200645)

Concurrent ICI-myocarditis must be excluded if cancer history — overlap with SLE flare changes management

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningsle_flare_with_multi_organ_involvement_and_myocarditis
    Active SLE flare (rising dsDNA + falling C3/C4 + clinical symptoms) with concurrent myocarditis + nephritis ± neuropsychiatric SLE — multi-organ life-threatening flare
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningconcurrent_ici_myocarditis_overlap
    Cancer patient on checkpoint inhibitor with new SLE-like flare — ICI-myocarditis (cardio.acute-hf.checkpoint-inhibitor-cardiotoxicity.v1) overlap with possible drug-induced lupus or true SLE flare
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverelupus_nephritis_worsening_on_acei_arb
    Worsening lupus nephritis (rising creatinine + active sediment + worsening proteinuria) after ACEi/ARB initiation in setting of acute flare and AKI
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverensaid_exposure_with_aki_in_sle
    NSAID administration in SLE patient (often peri-arthritis) precipitating AKI on lupus nephritis baseline
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverelibman_sacks_endocarditis_with_intracardiac_thrombus
    Echo shows Libman-Sacks valve thickening with intracardiac thrombus or embolic complication (stroke, splinter hemorrhages)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

SLE myocarditis ADHF — immunosuppression phenotype (EULAR 2023 SLE + AHA 2020 myocarditis PMID 32200645)
axis: sle_myocarditis_immunosuppression_phenotype
Selected axis "SLE myocarditis ADHF — immunosuppression phenotype (EULAR 2023 SLE + AHA 2020 myocarditis PMID 32200645)" by default fallback (first axis)
  • methylprednisolone
    first line
    glucocorticoid_iv_pulse
    1 g IV daily × 3-5 d (pulse), then transition to prednisone 1 mg/kg PO daily • IV • daily × 3-5 d pulse
    triggers: sle_myocarditis_confirmed, severe_organ_threatening_sle_flare
    EULAR 2023 SLE — pulse methylprednisolone for severe organ-threatening flare; AHA 2020 myocarditis statement (PMID 32200645) supports immunosuppression in autoimmune myocarditis
    rxcui 6902
  • prednisone
    first line
    glucocorticoid_oral
    1 mg/kg PO daily after pulse, taper over 6-12 mo • PO • daily with slow taper
    triggers: post_pulse_methylprednisolone_maintenance
    Standard EULAR 2023 SLE maintenance after pulse therapy
    rxcui 8640
  • cyclophosphamide
    first line
    alkylating_immunosuppressant
    500-1000 mg/m² IV pulse monthly × 6 (NIH protocol) • IV • monthly × 6 pulses
    triggers: severe_sle_myocarditis_with_organ_threat, rapid_clinical_deterioration_despite_steroids
    NIH cyclophosphamide protocol for severe organ-threatening SLE; long track record in lupus nephritis + myocarditis case series
    rxcui 3002
  • mycophenolate mofetil
    first line
    antimetabolite_immunosuppressant
    1 g PO BID, titrate to 1.5 g BID over 2 wk • PO • BID
    triggers: sle_myocarditis_with_lupus_nephritis_overlap, cyclophosphamide_intolerant_or_avoiding_gonadotoxicity
    ALMS PMID 19369404 — non-inferior to cyclophosphamide in lupus nephritis induction; preferred for women of reproductive age
    rxcui 68149
  • rituximab
    add on
    anti_cd20_monoclonal_antibody
    1 g IV × 2 doses 2 wk apart (or 375 mg/m² weekly × 4) • IV • induction protocol
    triggers: refractory_sle_myocarditis_despite_steroids_and_cytotoxic, overlap_with_b_cell_predominant_pathology
    Off-label but supported in observational SLE refractory series; B-cell depletion attenuates autoantibody production
    rxcui 121191
  • IVIG
    add on
    pooled_human_immunoglobulin
    2 g/kg IV divided over 2-5 d • IV • induction or refractory bridge
    triggers: refractory_or_bridge_to_other_immunosuppression, concurrent_infection_precluding_high_dose_steroids
    Refractory autoimmune myocarditis salvage; bridge when infection complicates steroid escalation
    rxcui 1426680
  • hydroxychloroquine
    first line
    antimalarial_dmard
    5 mg/kg PO daily (max 400 mg/d) • PO • daily lifelong
    triggers: sle_diagnosis_confirmed
    EULAR 2023 SLE — all SLE patients should receive HCQ for flare prevention; LUMINA cohort showed cardiac mortality reduction; baseline ophthalmology + annual screening for retinopathy
    rxcui 5521
  • furosemide
    first line
    loop_diuretic
    20-40 mg IV (diuretic-naive starting per DOSE PMID 21366472) • IV • q12h with reassessment
    triggers: volume_overload_in_sle_myocarditis_adhf
    Standard ADHF diuretic; gentle if cardiogenic shock
    rxcui 4603
  • warfarin
    comorbidity specific
    vitamin_k_antagonist
    5 mg PO daily, INR target 2-3 • PO • daily
    triggers: libman_sacks_endocarditis_with_intracardiac_thrombus, antiphospholipid_syndrome_with_thrombosis
    APL syndrome anticoagulation + Libman-Sacks intracardiac thrombus → warfarin (DOACs inferior in APL per TRAPS PMID 30002145, RAPS)
    rxcui 11289

outpatient playbook — drug actions (4)

  1. 1. maintenance HCQ lifelong
    rxcui 5521
    5 mg/kg PO daily (max 400 mg/d) • PO • daily lifelong
    trigger: SLE maintenance
    LUMINA + EULAR 2023
  2. 2. DMARD per SLE phenotype
    rxcui 6932
    mycophenolate 1-1.5 g BID OR azathioprine 2 mg/kg daily OR methotrexate 15-25 mg weekly • PO • as scheduled
    trigger: SLE maintenance per organ involvement
    EULAR 2023 SLE maintenance options
  3. 3. continue GDMT 4-pillar if HFrEF persists
    rxcui 593411
    empagliflozin 10 mg + carvedilol + ARNI + MRA at max tolerated • PO • as scheduled
    trigger: EF <40 maintained
    ACC/AHA 2022 HF guideline + EMPA-REG / DAPA-HF
  4. 4. low-dose prednisone if needed
    rxcui 8640
    5-7.5 mg PO daily (chronic steroid sparing) • PO • daily
    trigger: flare control inadequate on DMARD alone
    EULAR 2023 — use lowest tolerable dose

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: New HF symptoms in patient with established SLE or recently positive ANA + dsDNA + low complement; Young woman (15-45) with new HF + pleuritic chest pain + arthritis + rash → SLE myocarditis screen; ANA ≥1:80 + low C3/C4 + elevated troponin without obstructive CAD on cath.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**ADHF in SLE myocarditis** (cardio.acute-hf.lupus-myocarditis.v1).
Phenotype framing: SLE myocarditis vs viral myocarditis vs ICI-myocarditis (cancer + ICI exposure overlap) vs giant-cell myocarditis vs eosinophilic myocarditis vs sarcoid
Scope: SLE myocarditis presenting as ADHF — phenotype-first triage (immunosuppression-responsive vs concurrent ICI-myocarditis vs Libman-Sacks endocarditis with embolic complication)

No severity triggers fired against current inputs.

Plan

Regimen axis: **SLE myocarditis ADHF — immunosuppression phenotype (EULAR 2023 SLE + AHA 2020 myocarditis PMID 32200645)**.
1. methylprednisolone 1 g IV daily × 3-5 d (pulse), then transition to prednisone 1 mg/kg PO daily IV daily × 3-5 d pulse (glucocorticoid_iv_pulse, first line) — EULAR 2023 SLE — pulse methylprednisolone for severe organ-threatening flare; AHA 2020 myocarditis statement (PMID 32200645) supports immunosuppression in autoimmune myocarditis
2. prednisone 1 mg/kg PO daily after pulse, taper over 6-12 mo PO daily with slow taper (glucocorticoid_oral, first line) — Standard EULAR 2023 SLE maintenance after pulse therapy
3. cyclophosphamide 500-1000 mg/m² IV pulse monthly × 6 (NIH protocol) IV monthly × 6 pulses (alkylating_immunosuppressant, first line) — NIH cyclophosphamide protocol for severe organ-threatening SLE; long track record in lupus nephritis + myocarditis case series
4. mycophenolate mofetil 1 g PO BID, titrate to 1.5 g BID over 2 wk PO BID (antimetabolite_immunosuppressant, first line) — ALMS PMID 19369404 — non-inferior to cyclophosphamide in lupus nephritis induction; preferred for women of reproductive age
5. rituximab 1 g IV × 2 doses 2 wk apart (or 375 mg/m² weekly × 4) IV induction protocol (anti_cd20_monoclonal_antibody, add on) — Off-label but supported in observational SLE refractory series; B-cell depletion attenuates autoantibody production
6. IVIG 2 g/kg IV divided over 2-5 d IV induction or refractory bridge (pooled_human_immunoglobulin, add on) — Refractory autoimmune myocarditis salvage; bridge when infection complicates steroid escalation
7. hydroxychloroquine 5 mg/kg PO daily (max 400 mg/d) PO daily lifelong (antimalarial_dmard, first line) — EULAR 2023 SLE — all SLE patients should receive HCQ for flare prevention; LUMINA cohort showed cardiac mortality reduction; baseline ophthalmology + annual screening for retinopathy
8. furosemide 20-40 mg IV (diuretic-naive starting per DOSE PMID 21366472) IV q12h with reassessment (loop_diuretic, first line) — Standard ADHF diuretic; gentle if cardiogenic shock
9. warfarin 5 mg PO daily, INR target 2-3 PO daily (vitamin_k_antagonist, comorbidity specific) — APL syndrome anticoagulation + Libman-Sacks intracardiac thrombus → warfarin (DOACs inferior in APL per TRAPS PMID 30002145, RAPS)

Setting playbook (outpatient) — Long-term cardiology + rheumatology co-management: SLE flare prevention with HCQ + DMARD + steroid taper; GDMT 4-pillar maintenance for residual HFrEF; ICD eval per HRS 2017 if EF <35 + sustained VT despite ≥3 mo therapy; cardiac MRI at 3 mo + 1 yr to confirm resolution
10. maintenance HCQ lifelong 5 mg/kg PO daily (max 400 mg/d) PO daily lifelong — SLE maintenance (LUMINA + EULAR 2023)
11. DMARD per SLE phenotype mycophenolate 1-1.5 g BID OR azathioprine 2 mg/kg daily OR methotrexate 15-25 mg weekly PO as scheduled — SLE maintenance per organ involvement (EULAR 2023 SLE maintenance options)
12. continue GDMT 4-pillar if HFrEF persists empagliflozin 10 mg + carvedilol + ARNI + MRA at max tolerated PO as scheduled — EF <40 maintained (ACC/AHA 2022 HF guideline + EMPA-REG / DAPA-HF)
13. low-dose prednisone if needed 5-7.5 mg PO daily (chronic steroid sparing) PO daily — flare control inadequate on DMARD alone (EULAR 2023 — use lowest tolerable dose)

Non-pharmacologic actions:
- Lifestyle (sun avoidance, smoking cessation accelerates SLE atherosclerosis)
- Vaccinations annually (inactivated influenza, pneumococcal)
- Cardiac rehab if residual HFrEF
- Pregnancy planning consultation (HCQ continued; mycophenolate teratogenic)

AVOID / contraindication checks:
- Nsaids_avoid_in_sle_with_renal_involvement (lupus nephritis + AKI risk)
- Strongyloides_serology_required_before_high_dose_steroids (hyperinfection risk)
- Cyclophosphamide_gonadotoxic_consider_fertility_preservation (sperm/oocyte cryopreservation before cycles)
- Hydroxychloroquine_baseline_ophthalmology_then_annual (retinopathy screening per AAO)
- Doac_inferior_to_warfarin_in_triple_positive_apl (TRAPS PMID 30002145)
- Live_vaccines_avoid_during_immunosuppression (MMR, varicella, yellow fever)

Monitoring

Regimen monitoring:
- troponin daily during immunosuppression response marker
- c3 c4 dsdna weekly during steroid taper flare surveillance
- cbc bmp lft q2wk during cyclophosphamide or mycophenolate
- urinalysis for lupus nephritis progression
- echo at 2wk and 3mo for lvef recovery
- cmr at 3mo to confirm inflammation resolution
- pneumocystis jirovecii prophylaxis with tmp smx during high dose steroids

Setting (outpatient) monitoring:
- Quarterly clinic + annual full restage
- CMR at 3 mo + 1 yr
- Cross-link to advanced HF if NYHA III on max therapy

Follow-up plan: Long-term rheumatology + cardiology co-management; SLE flare prevention with HCQ + DMARD; GDMT 4-pillar for residual HFrEF; ICD eval per HRS 2017 if EF <35 + sustained VT despite ≥3 mo GDMT + immunosuppression
- Close-out criterion: long-term plan booked

Monitoring phase: Daily troponin trend (response marker); weight + BMP + UA; weekly C3/C4 + dsDNA during steroid taper; echo at 2 wk + 3 mo; CMR at 3 mo to confirm resolution

Disposition

Current setting: outpatient — Long-term cardiology + rheumatology co-management: SLE flare prevention with HCQ + DMARD + steroid taper; GDMT 4-pillar maintenance for residual HFrEF; ICD eval per HRS 2017 if EF <35 + sustained VT despite ≥3 mo therapy; cardiac MRI at 3 mo + 1 yr to confirm resolution

Disposition criteria:
- Long-term continuation; cross-link to cardio.hf.core.v1 for residual HFrEF management; cross-link to cardio.acute-hf.core.v1 for inpatient decompensations

Escalation triggers (move to higher acuity):
- Recurrent SLE flare → rheumatology rescue immunosuppression
- Refractory HFrEF on max GDMT → advanced HF / transplant evaluation
- ICD therapy delivered → urgent EP

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Active SLE flare (rising dsDNA + falling C3/C4 + clinical symptoms) with concurrent myocarditis + nephritis ± neuropsychiatric SLE — multi-organ life-threatening flare
- [LIFE_THREATENING] Cancer patient on checkpoint inhibitor with new SLE-like flare — ICI-myocarditis (cardio.acute-hf.checkpoint-inhibitor-cardiotoxicity.v1) overlap with possible drug-induced lupus or true SLE flare
- [SEVERE] Worsening lupus nephritis (rising creatinine + active sediment + worsening proteinuria) after ACEi/ARB initiation in setting of acute flare and AKI

Citations

- EULAR 2023 SLE recommendations + AHA 2020 myocarditis scientific statement (PMID 32200645) + ACR 2019 SLE classification (Aringer PMID 31385462) + ESC 2013 myocarditis (Caforio PMID 23824828) [PMID:32200645](https://pubmed.ncbi.nlm.nih.gov/32200645/)
- Cited evidence (PMID 31385462) [PMID:31385462](https://pubmed.ncbi.nlm.nih.gov/31385462/)
- Cited evidence (PMID 23824828) [PMID:23824828](https://pubmed.ncbi.nlm.nih.gov/23824828/)
- Cited evidence (PMID 30290974) [PMID:30290974](https://pubmed.ncbi.nlm.nih.gov/30290974/)
- Cited evidence (PMID 30217631) [PMID:30217631](https://pubmed.ncbi.nlm.nih.gov/30217631/)

Last reconciled with current guidelines: 2026-05-15.
References
  • EULAR 2023 SLE recommendations + AHA 2020 myocarditis scientific statement (PMID 32200645) + ACR 2019 SLE classification (Aringer PMID 31385462) + ESC 2013 myocarditis (Caforio PMID 23824828) — PMID:32200645
  • Cited evidence (PMID 31385462) — PMID:31385462
  • Cited evidence (PMID 23824828) — PMID:23824828
  • Cited evidence (PMID 30290974) — PMID:30290974
  • Cited evidence (PMID 30217631) — PMID:30217631